Ifenprodil is a non-competitive antagonist of the NMDA receptor subtype, particularly those containing the GluN2B subunit, and is investigated for its potential in treating neurological conditions such… Read more
Ifenprodil is a non-competitive antagonist of the NMDA receptor subtype, particularly those containing the GluN2B subunit, and is investigated for its potential in treating neurological conditions such as neurodegenerative diseases and ischemic stroke. By modulating glutamatergic neurotransmission, this compound serves as a significant subject in neuropharmacological research. Laboratories require high-quality reference standards, including the hemitartrate salt form and metabolic derivatives like Ifenprodil Glucuronide, to conduct precise analytical testing and method validation. These compounds are essential for accurate impurity profiling and quantitative analysis throughout pharmaceutical development. Using these specialized materials ensures that researchers can reliably monitor the stability and purity of the parent drug, supporting rigorous quality control protocols during the synthesis and characterization of potential therapeutic agents and their associated metabolites.